Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

This study is currently recruiting participants.
Verified August 2013 by University of California, San Francisco
Sponsor:
Collaborators:
Celgene Corporation
Genentech
Information provided by (Responsible Party):
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT01542918
First received: February 27, 2012
Last updated: August 13, 2013
Last verified: August 2013

February 27, 2012
August 13, 2013
December 2012
June 2015   (final data collection date for primary outcome measure)
To establish the maximal tolerated dose (MTD) of Lenalidomide in patients with recurrent CNS NHL and intraocular NHL [ Time Frame: Participants will be followed for the duration of treatement, an expected average of 4 months. ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01542918 on ClinicalTrials.gov Archive Site
  • To define the extent of cerebrospinal fluid (CSF) penetration of lenalidomide. [ Time Frame: Participants will have CSF withdrawn every 4 weeks while on treatment. Average study participation is approximately 4 months. ] [ Designated as safety issue: No ]
  • To assess the clinical efficacy Lenalidomide monotherapy as measured by cytologic, neurologic, radiographic, and ocular (for patients with intraocular lymphoma) response criteria. [ Time Frame: Participants will have weekly evaluations at clinic visits for the duration of treatment. Average study participation is approximately 4 months. ] [ Designated as safety issue: No ]
  • To define the immunological effects of lenalidomide using flow-cytometry CSF as well as genomic markers of recurrent/refractory CNS lymphoma. [ Time Frame: Participants will have CSF withdrawn every 4 weeks while on treatment. Average study participation is approximately 4 months. ] [ Designated as safety issue: No ]
  • To assess the clinical efficacy of combined intraventricular plus systemic rituximab administration in combination with lenalidomide as measured by cytologic, neurologic, and radiographic response criteria. [ Time Frame: Participants will have weekly evaluations at clinic visits for the duration of treatment. Average study participation is approximately 4 months. ] [ Designated as safety issue: No ]
    Objective only applies to patients with recurrent CNS lymphoma not responding to lenalidomide as monotherapy
  • To determine a potential impact of intravenous rituximab administration on the rate of rituximab clearance from the CSF after intraventricular rituximab administration. [ Time Frame: Participants will have CSF withdrawn every 4 weeks while on treatment. Average study participation is approximately 4 months. ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

This is a Phase I study, which means that the goal is to see if the study treatment is safe. The purpose of this study is to test the safety of Lenalidomide at different dose levels, and to test the safety of Lenalidomide alone or in combination with Rituximab (also known as Rituxan®).

Rationale for the Proposed Study

There is evidence that immunomodulatory drugs such as lenalidomide stimulate immune effectors such as natural killer (NK) cells, and thus promote rituximab efficacy via ADCC. Because of the evidence for synergy between rituximab and lenalidomide in NHL, patients who do not respond to lenalidomide monotherapy will receive combined intravenous plus intraventricular rituximab in addition to lenalidomide. To maximize delivery to the central nervous system (CNS), the investigators propose to administer rituximab via both intravenous and intraventricular routes. The rationale for intraventricular administration of rituximab is the demonstration that approximately 0.1% of systemically administered rituximab penetrates the cerebral spinal fluid (CSF) but that intraventricular administration of rituximab is both feasible and achieves high concentrations that are associated with anti-lymphoma activity. This study will thus build upon the two Phase 1 trials of intraventricular rituximab that have been conducted at UCSF to define the safety of the intraventricular route of administration; this study will, however, be the first to evaluate the combination of intraventricular plus intravenous treatment.

The rationale for intravenous administration of rituximab in recurrent CNS lymphoma is that the blood-brain-barrier is likely partially disrupted, particularly when there is lymphoma-associated contrast enhancement detectable on the MRI, and the fact that there is evidence for activity when rituximab is administered intravenously, both as monotherapy (Batchelor et al., 2011) and potentially in combination with chemotherapy.

Interventional
Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Recurrent/Refractory CNS
  • Intraocular Lymphoma
  • Drug: Lenalidomide

    Formulation of Dosage forms: 5 mg, 10 mg, 15 mg and 25 mg capsules.

    Dosage: 10 mg - 30 mg (Treatment 1 and Treatment 2)

    Route of administration: Oral

    Other Name: Revilimid
  • Drug: Rituximab

    Formulation of Dosage forms: 100 mg/IO mL and 500 mg/50 mL solution in a single-use vial

    Dosage: 375 mg/m2, intravenous (Treatment 2, Cycle 1 only); 25 mg intraventricular injection (Treatment 2, all cycles)

    Route of administration: Intravenous (Treatment 2, Cycle 1 only); Intraventricular injection (Treatment 2, all cycles)

    Other Names:
    • Rituxan
    • MabThera
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
18
June 2017
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Ability to give written informed consent and willingness to comply with the requirements of the protocol
  • Age eighteen years or older
  • Tumors must be CD20+ on prior pathologic analysis
  • All prospective participants must have an Ommaya reservoir (or equivalent ventricular access device) inserted as part of their standard clinical care prior to initiation of study treatment.
  • No concurrent methotrexate, thiotepa, cytarabine, or investigational agents
  • Absolute neutrophil count (ANC) > 1,500 (growth factors permitted)
  • Platelets >50,000 (platelet transfusion allowed)
  • Total bilirubin </= 1.5 x ULN
  • AST (SGOT) and ALT (SGPT) </= 3 x ULN.
  • Stable dose of glucocorticoids pre-therapy. If patients are receiving dexamethasone, the dose of dexamethasone should not increase during the 96 hours prior to initiation of therapy.
  • Renal function assessed by calculated creatinine clearance. Patients must have calculated creatinine clearance >/= 60ml/min by Cockcroft-Gault formula or 24 hour urine demonstrating CrCl >/= 60ml/min .
  • Females of childbearing potential (FCBPs)† must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days and again within 24 hours prior to receiving lenalidomide for Cycle 1 and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBPs must also agree to ongoing pregnancy testing and for 28 days after receiving their last dose of lenalidomide.
  • Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy.
  • Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to aspirin may use warfarin or low molecular weight heparin).
  • All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®.

Exclusion Criteria:

  • Intraventricular chemotherapy or radiation therapy within 4 days of starting treatment
  • Intravenous rituximab within 30 days of starting treatment
  • Persistent neurotoxicity from intraventricular methotrexate, cytarabine, thiotepa
  • Anticipated survival of less than 1 month
  • Pregnant women and women of child-bearing potential who are not using an effective method of birth control.
  • Known hypersensitivity to thalidomide or lenalidomide
  • The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
  • Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.
  • Contraindication to aspirin. If unable to take aspirin, contraindication to warfarin or low molecular weight heparin.
Both
18 Years and older
No
Contact: James Rubenstein, MD, PhD 415-502-4430 jamesr@medicine.ucsf.edu
United States
 
NCT01542918
112530
Yes
University of California, San Francisco
University of California, San Francisco
  • Celgene Corporation
  • Genentech
Principal Investigator: James Rubenstein, MD, PhD University of California, San Francisco
University of California, San Francisco
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP